We are a group of Biopharmaceutical companies
from Europe innovating in Anti-Microbial resistance research
The emergence of multi-drug resistant bacteria presents a global public health crisis which demands the development of new antibiotics, preventive or alternative strategies, yet the R&D investment from large pharmaceutical companies is on the wane due to lack of attractiveness of investment in this therapeutic area.
Innovation is thus largely driven by small and medium biopharma companies, and European nations need to engage more extensively in supporting this innovation via new policies and R&D stimulating incentives.
The BEAM Alliance will work to improve the regulatory, investment, and commercial environments in Europe for research, development, approval and market viability of new products combating antimicrobial resistance.
European small and medium biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance.
Members a unique voice to propose and support policies and incentives to identified issues in Europe.
With the existing community of stakeholders dedicated to implementing tangible solutions.
Bold incentives that warrant action by policymakers to stimulate innovation by biopharma companies.
April 2015. Presentation of an ePoster at the Pipeline Corner @ECCMID, 25th European Congress of Clinical Microbiology and Infectious Diseases, 25 - 28 April 2015 in Copenhagen. Download the poster here! The Pipeline Corner was mentioned in the press here and here.
30 September 2015. Publication of the Alliance's Position Paper: key measures to
research across Europe. The BEAM Alliance urges European and national public authorities to take
three key short term actions with immediate effect: (1) create a specific fund dedicated to small and medium biopharmas developing
innovative antibacterial products, (2) enhance market incentives to increase the Return on Investment for products
tackling antimicrobial resistance through the creation of a special status, (3) simplify regulatory pathways for products
Download the position paper, the English press release, the French press release.
January 2016. Signature of the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
The BEAM Alliance signed the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance that was launched on January 21, 2016. The declaration calls upon governments to work with global pharmaceutical, diagnostics and biotechnology industries to develop new ways to provide sustainable market models for antibiotics and commit the funds needed to implement them. The BEAM Alliance and the other signatories commit themselves to further action in reducing the development of drug resistance, increasing investment in R&D to meet public health needs and to improve access to high-quality antibiotics for all.
Learn more here.
May 2016. The BEAM Alliance becomes an associated member to DRIVE-AB!
19 May 2016. The BEAM Alliance The Beam Alliance fully supports Jim O’Neill’s Comprehensive Plan to Combat Superbugs!
Biotech companies such as members of the BEAM Alliance are strongly supportive of the vision and pragmatic solutions proposed by the UK Review on AMR. It is the first time such a thorough global economic analysis on the threat on AMR with long-time projections is published. We, as actors of innovation in the field, face every day the funding needs, path to market and other healthcare payers issues well raised by the Jim O’Neil team, which limit and even sometimes prevent us from translating potential great innovative ideas to products on the market.
The Global Innovation Fund, Market entry and Diagnostic Rewards, the promotion of novel alternative and preventives solutions, and overall better rewards to innovation by National healthcare purchase and distribution systems on AMR solutions, are all ambitious but required actions to radically change the current crisis situation.
We are hopeful that worldwide leaders will not only acknowledge conclusions of this report, but actually decide to join forces and act now to win the battle against resistance to antibiotics. Read the press release and the full report for the action plan.
16 January 2017. The BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) today announces the election of its new Board of Directors further to its Extraordinary General Assembly held in Paris on 20 December 2016.
Download the press release.